DUBLIN, Ohio, Jan. 3, 2023 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2023 on February 2, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern.
To access the webcast and corresponding slide presentation, visit Cardinal Health's Investor Relations page. No access code is required. Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months.
About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 years in business, operations in more than 30 countries and approximately 46,500 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com.
Media: | Erich Timmerman |
(614) 757-8231 | |
This email address is being protected from spambots. You need JavaScript enabled to view it. | |
Investors: | Kevin Moran |
(614) 757-7942 | |
This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$129.30 |
| Daily Change: | 0.55 0.43 |
| Daily Volume: | 1,727,941 |
| Market Cap: | US$31.290B |
November 20, 2024 November 11, 2024 November 01, 2024 October 29, 2024 September 20, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
